[{"id":"341bd1dd-ae91-47b3-a8bb-d90e76eb4052","acronym":"BYON4228.001","url":"https://clinicaltrials.gov/study/NCT05737628","created_at":"2023-02-21T15:01:28.796Z","updated_at":"2024-07-02T16:35:13.672Z","phase":"Phase 1","brief_title":"First-in-human Dose Escalation and Expansion Study With the SIRPα-directed Monoclonal Antibody BYON4228","source_id_and_acronym":"NCT05737628 - BYON4228.001","lead_sponsor":"Byondis B.V.","biomarkers":" CD20","pipe":" | ","alterations":" CD20 expression","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Truxima (rituximab-abbs) • BYON4228"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 03/04/2024","start_date":" 03/04/2024","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-03-20"}]